EP1830825A1 - Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie - Google Patents

Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie

Info

Publication number
EP1830825A1
EP1830825A1 EP05850545A EP05850545A EP1830825A1 EP 1830825 A1 EP1830825 A1 EP 1830825A1 EP 05850545 A EP05850545 A EP 05850545A EP 05850545 A EP05850545 A EP 05850545A EP 1830825 A1 EP1830825 A1 EP 1830825A1
Authority
EP
European Patent Office
Prior art keywords
gsh
level
increasing
compound capable
hair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05850545A
Other languages
German (de)
English (en)
French (fr)
Inventor
Stéphane COMMO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of EP1830825A1 publication Critical patent/EP1830825A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/10—Preparations for permanently dyeing the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • composition according to the invention may be administered orally or applied topically to the skin (on any cutaneous area of the body covered with hair) and / or the scalp.
  • the oleosomes consist of an oil-in-water emulsion formed by oily globules provided with a lamellar liquid crystal coating dispersed in an aqueous phase (see patent applications EP 0 641 557 and EP 0 705 593).
  • the senescent response can be determined by any method making it possible to reveal cellular senescence, for example, determination of a shortening of the telomeres, measurement of telomerase activity (TRAPeze kit, Intergen), determination of the decrease in the rate of cyclin E, determination of the decrease in the level of phosphorylated Rb protein (Bandyopadhyay D et al., Experimental Gerontology 2001: 36: 1265-1275), measurement of beta-galactosidase activity (Dimri GP et al., PNAS 1995; 92: 9363 -9367)
  • the cell viability is measured 24h after the stress using 2 ', 7'-dichlorodihydrofluorescein diacetate (H 2 DCFDA, D399, Molecular Probes).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP05850545A 2004-12-22 2005-12-20 Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie Ceased EP1830825A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0413756A FR2879444B1 (fr) 2004-12-22 2004-12-22 Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie
PCT/FR2005/003196 WO2006070101A1 (fr) 2004-12-22 2005-12-20 Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie

Publications (1)

Publication Number Publication Date
EP1830825A1 true EP1830825A1 (fr) 2007-09-12

Family

ID=34952658

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05850545A Ceased EP1830825A1 (fr) 2004-12-22 2005-12-20 Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie

Country Status (7)

Country Link
US (1) US8481762B2 (ja)
EP (1) EP1830825A1 (ja)
JP (1) JP5730462B2 (ja)
KR (3) KR101078635B1 (ja)
CN (1) CN101087584B (ja)
FR (1) FR2879444B1 (ja)
WO (1) WO2006070101A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990048305A (ko) * 1997-12-09 1999-07-05 성재갑 피부미백용 조성물
FR2902325B1 (fr) * 2006-06-20 2009-12-04 Oreal Utilisation de 3h-1,2-dithiole-3-thione, d'anethole dithiomlethione, de sulforaphe, de phenethyl isothiocyanate, de 6-methyle-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie
FR2902329B1 (fr) * 2006-12-19 2011-07-01 Oreal Utilisation de sulforaphane, de phenethyl isothiocyanate, de 6-methyl-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie.
JP5956107B2 (ja) * 2010-11-13 2016-07-20 学校法人昭和大学 皮膚および毛髪の黒化促進剤、その黒化促進剤を含む黒化促進用外用剤および黒化促進用飲食品
KR101576336B1 (ko) 2013-12-19 2015-12-11 바이오스펙트럼 주식회사 샤스타데이지 추출물을 유효성분으로 포함하는 피부상태 개선용, 또는 항산화용 조성물
JP2019531344A (ja) 2016-09-12 2019-10-31 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法
JP2019533008A (ja) 2016-09-12 2019-11-14 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
CN112057459A (zh) * 2020-10-14 2020-12-11 中国药科大学 咖啡豆醇的防脱发和生发用途
EP4292581A1 (en) 2022-06-16 2023-12-20 Bella Aurora Labs, S.A. Hair repigmenting composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0545147A2 (de) * 1991-12-04 1993-06-09 Wella Aktiengesellschaft Verwendung von Radikalfängern und/oder zur Deaktivierung nicht-radikalischer, reaktiver Sauerstoffspezies geeigneter Substanzen zur Verhinderung oder Verzögerung des Ergrauens von menschlichen Haaren
US5928654A (en) * 1996-04-17 1999-07-27 Societe L'oreal S.A. Modulating body/cranial hair growth with lipoxygenase/cyclooxygenase inhibitors
US6716437B1 (en) * 1993-09-13 2004-04-06 E-L Management Corporation Topical composition and method for enhancing lipid barrier synthesis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU82323A1 (fr) * 1980-04-02 1981-12-02 Oreal Utilisation de l'huile de cafe comme agent filtrant solair,composition et procede de protection la mettant en oeuvre
JPH0377809A (ja) * 1989-08-21 1991-04-03 Arusoa Sogo Kenkyusho:Kk 養毛料
US7556825B2 (en) * 1993-04-02 2009-07-07 Anticancer, Inc. Method for promoting hair growth
FR2704754B1 (fr) * 1993-05-07 1995-06-30 Oreal Utilisation d'un alkyle ester de glutathion dans une composition cosmetique ou dermatologique destinee au traitement par voie topique du vieillissement cutane.
JPH072677A (ja) * 1993-06-18 1995-01-06 Toyo Seito Kk 経口育毛剤
FR2711060B1 (fr) * 1993-10-13 1995-11-17 Oreal Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet.
EP0656201A1 (en) * 1993-11-09 1995-06-07 Transcend Therapeutics, Inc. Use of stimulators of glutathione synthesis as hait growth promotors
US6103689A (en) * 1994-08-31 2000-08-15 Trustees Of Boston University Methods of inducing hair growth and coloration
US6867179B1 (en) * 1994-08-31 2005-03-15 Trustees Of Boston University Methods of inducing hair growth and coloration
US6110474A (en) * 1997-05-13 2000-08-29 E-L Management Corp. Cosmetic compositions containing a coffee extract pigment
GB9720372D0 (ja) * 1997-07-09 1997-11-26 Reckitt & Colman France
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
US20020155163A1 (en) * 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
WO2001085142A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
AU2001270554A1 (en) * 2000-06-06 2001-12-17 Basf Aktiengesellschaft Use of an (r)-enantiomer of lipoic acid in cosmetics and dermatologicals
FR2820036B1 (fr) * 2001-01-26 2005-12-09 L M D Utilisation d'un isothiocyanate, d'un thiocyanate ou de leur melange en tant que depigmentant
FR2826261B1 (fr) * 2001-06-26 2005-03-25 Lmd Composition a usage topique comprenant un produit cytotoxique et son utilisation dans le traitement de l'alopeche
FR2834718B1 (fr) * 2002-01-15 2004-12-24 Cognis France Sa Substances actives cosmetiques et/ou pharmaceutiques
ES2193874B1 (es) * 2002-04-03 2005-03-01 Puleva Biotech, S.A. Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
JP4285939B2 (ja) * 2002-04-25 2009-06-24 株式会社ノエビア 皮膚外用剤
FR2840530B1 (fr) * 2002-06-11 2004-12-24 Oreal Composition cosmetique comprenant un agent inducteur de l'expression de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
EP1515688B1 (fr) * 2002-06-11 2013-07-24 L'Oréal Utilisation d'un complexe salen-manganèse comme agent protecteur des mélanocytes du follicule pileux et applications cosmétiques
KR20040000072A (ko) * 2002-06-24 2004-01-03 현대자동차주식회사 머플러의 물배출장치
US20060083796A1 (en) * 2002-09-09 2006-04-20 Sylvie Pridmore-Merten Orally administrable composition for improving hair and coat quality
KR100476069B1 (ko) * 2003-02-12 2005-03-10 주식회사 태평양 １，２－디티올티온 유도체를 함유하는 발모촉진용 또는탈모방지용 조성물
WO2004103334A1 (en) * 2003-05-20 2004-12-02 Sederma Slimming cosmetic composition comprising cafestol or kahweol
FR2863484B1 (fr) * 2003-12-11 2007-04-13 Oreal Utilisation de composes capables d'agir sur la voie metabolique controlee par la dopachrome tautomerase trp-2 comme agent protecteur des melanocytes du follicule pileux et applications
EP1616551A1 (fr) * 2004-07-13 2006-01-18 L'oreal Procédé de traitement cosmétique pour prévenir ou retarder les signes du vieillissement cutané
CA2584767A1 (en) * 2004-10-25 2006-05-04 Symrise Gmbh & Co. Kg Use of glycosylated flavanones for the browning of skin or hair

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0545147A2 (de) * 1991-12-04 1993-06-09 Wella Aktiengesellschaft Verwendung von Radikalfängern und/oder zur Deaktivierung nicht-radikalischer, reaktiver Sauerstoffspezies geeigneter Substanzen zur Verhinderung oder Verzögerung des Ergrauens von menschlichen Haaren
US6716437B1 (en) * 1993-09-13 2004-04-06 E-L Management Corporation Topical composition and method for enhancing lipid barrier synthesis
US5928654A (en) * 1996-04-17 1999-07-27 Societe L'oreal S.A. Modulating body/cranial hair growth with lipoxygenase/cyclooxygenase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMOREPACIFIC CORP ET AL: "COMPOSITION FOR RESTORING HAIR OR PREVENTING DEPILATION CONTAINING 1,2-DITHIOLTHIONE DERIVATIVE", 18 August 2004 (2004-08-18), XP055132733, Retrieved from the Internet <URL:http://kposd.kipo.go.kr:8088/kiponet/up/kpion/pdfDownload.do?pdfFileName=out_PDF_cw_gaz_p_1020030008765_EN.pdf> [retrieved on 20140731] *
See also references of WO2006070101A1 *

Also Published As

Publication number Publication date
US20080014229A1 (en) 2008-01-17
FR2879444A1 (fr) 2006-06-23
US8481762B2 (en) 2013-07-09
WO2006070101A1 (fr) 2006-07-06
JP2008525387A (ja) 2008-07-17
FR2879444B1 (fr) 2007-05-18
KR101165648B1 (ko) 2012-07-19
JP5730462B2 (ja) 2015-06-10
KR20120116900A (ko) 2012-10-23
CN101087584B (zh) 2010-06-23
KR101078635B1 (ko) 2011-11-01
KR20070086593A (ko) 2007-08-27
KR20100127890A (ko) 2010-12-06
CN101087584A (zh) 2007-12-12

Similar Documents

Publication Publication Date Title
EP1515688B1 (fr) Utilisation d&#39;un complexe salen-manganèse comme agent protecteur des mélanocytes du follicule pileux et applications cosmétiques
WO2006070101A1 (fr) Utilisation d&#39;un compose capable d&#39;augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie
EP1870081B1 (fr) Utilisation d&#39;acide ellagique pour le traitement de la canitie
FR2902325A1 (fr) Utilisation de 3h-1,2-dithiole-3-thione, d&#39;anethole dithiomlethione, de sulforaphe, de phenethyl isothiocyanate, de 6-methyle-sulphinyl)hexyl isothiocyanate et d&#39;allyl isothiocyanate pour le traitement de la canitie
CA2281193C (fr) Utilisation d&#39;au moins un extrait de rosacee du genre sanguisorba officinalis pour favoriser la pigmentation de la peau et/ou des poils et/ou des cheveux
FR2939030A1 (fr) Utilisation de la taurine pour le traitement de la canitie
EP1870087B1 (fr) Utilisation de la coumarine, de butylated hydroxyanisole et d&#39;ethoxyquine pour le traitement de la canitie
FR2902320A1 (fr) Utilisation de butylated hydroxyanisole pour le traitement de la canitie
EP1515687B1 (fr) Utilisation d&#39;un agent inducteur de l&#39;expression de la dopachrome tautomerase (TRP-2) comme agent protecteur des mélanocytes du follicule pileux
ES2431309T3 (es) Utilización de un complejo salen-manganeso como agente protector de los melanocitos del folículo piloso, y aplicaciones cosméticas
FR2863484A1 (fr) Utilisation de composes capables d&#39;agir sur la voie metabolique controlee par la dopachrome tautomerase trp-2 comme agent protecteur des melanocytes du follicule pileux et applications
FR2902321A1 (fr) Utilisation de curcumin pour le traitement de la canitie
FR2902329A1 (fr) Utilisation de sulforaphane, de phenethyl isothiocyanate, de 6-methyl-sulphinyl)hexyl isothiocyanate et d&#39;allyl isothiocyanate pour le traitement de la canitie.
FR2908652A1 (fr) Utilisation d&#39;ethoxuquine pour le traitement de la canitie
FR2951940A1 (fr) Utilisation d&#39;un extrait de caesalpinia pour lutter contre la canitie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100526

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20180419